Joanna Stankiewicz, MD
Hematology-Oncology · Chicago, ILNPI 1043258254
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,775 of the $1,992 with a category attached, or 89.1%. AstraZeneca accounts for 89.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $1,432, more than ten times the $114 reported in 2019.
Across 9 payments — averaging $221.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$103
- Pfizer$55
- Pharmaessentia USA Corporation$29
- Cardinal Health 108 LLC$18
- Gilead$12
What the payments were for
- Consulting fees$1,77589%
- Food & beverage$19410%
- Education$231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,775 |
| Amgen | 1 | $103 |
| Pfizer | 3 | $55 |
| Pharmaessentia USA Corporation | 1 | $29 |
| Cardinal Health 108 LLC | 1 | $18 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 26 | $458,359 |
| ImbruvicaIbrutinib | 21 | $323,571 |
| Lenalidomide | 28 | $277,033 |
| InlytaAxitinib | 12 | $235,440 |
| CalquenceAcalabrutinib Maleate | 14 | $217,797 |
| BrukinsaZanubrutinib | 14 | $212,202 |
| IbrancePalbociclib | 13 | $206,860 |
| Abiraterone Acetate | 21 | $85,089 |
| XgevaDenosumab | 17 | $54,451 |
| EliquisApixaban | 34 | $24,656 |
| Hydroxyurea | 31 | $1,386 |
| Letrozole | 13 | $785 |
| Anastrozole | 51 | $654 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $421 |
| Levothyroxine Sodium | 32 | $389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance, Eliquis | $55 | $466,95759 claims |
| AstraZenecaCalquence | $1,775 | $217,79714 claims |
| AmgenXgeva | $103 | $54,45117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Chicago
- Samir UndeviaChicago$2K
- Ann MauerChicago$1K
- Shawn KothariChicago$0
- Brandon BungoChicago$0
- Jane ChurpekChicago$0
- Michael HawkingChicago$0
- Megan RandallChicago$0
- John ShowelChicago$0
- Tabraiz MohammedChicago$0
- Sujatha RaoCarbondale$933
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.